Navigation Links
Large study finds ICS therapy reduces pneumonia mortality
Date:4/15/2011

Patients with chronic obstructive pulmonary disease (COPD) who are hospitalized for pneumonia and treated with inhaled corticosteroids (ICS) have decreased mortality when compared to those who are not treated with ICS, according to a retrospective analysis of almost 16,000 COPD patients admitted to VA hospitals.

The results were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Read the original study here.

The use of ICS in COPD patients reduces exacerbations, but increases the rate pneumonia. "It was therefore believed that it also increased mortality," said Eric Mortensen, MD, investigator at VERDICT (Veterans Evidence-based Research, Dissemination, and Implementation Center, a VA Health Services Research and Development program) and principal investigator on the study. "This was the first large rigorous study to examine whether this was in fact the case."

"This result is the opposite of what many experts have believed," said Dr. Mortensen. "We do, however, believe that this represents the reality because ours is one the largest studies, and employed a rigorous definition of pneumonia that previous studies did not."

Dr. Mortensen and colleagues examined the medical records of 15,768 COPD patients over the age of 65 who had been admitted to the VA hospitals for pneumonia between 2002 and 2007. About half of those patients had been treated with ICS (52.5 percent) and half were not (47.5 percent).

When they analyzed all-cause mortality of the two groups for both 30- and 90-day intervals, there were significant differences between the groups: for 30-day mortality, 10.2 percent of ICS users died, compared to 13.6 percent of those who were not treated with ICS. For 90-day mortality, the difference was even more striking: 17.3 percent among the ICS users died, and 22.8 percent of those who didn't receive ICS.

Overall, those who were not treated with ICS had about a 25 percent greater mortality risk than those who were treated with ICS.

"These results have clear implications for current clinical practice, which has been informed in the past by a series of studies that found an increased risk of pneumonia with ICS use," said Dr. Mortensen. "In contrast, our study would suggest that ICS use may confer a survival benefit to these patients and may be employed when there are not contraindications. These results should reassure clinicians that they can give their COPD patients ICS without fearing that the increased risk of pneumonia will translate into higher risk of mortality."

The next "really big question," according to Dr. Mortensen is whether ICS might be useful to initiate in certain sub-populations hospitalized with pneumonia. "There is currently a large randomized, controlled trial getting started that is looking at using oral versus intravenous steroids for all pneumonia patients," Dr. Mortensen explained. "The potential question is if this is successful would it be as useful to start these patients on inhaled (rather than oral or intravenous) steroids."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Effects of a large reduction in alcohol prices on mortality in Finland
2. Large weight gain raises risk for recurrence among breast cancer survivors
3. New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
4. Nick Jonas Lives Large, Despite Diabetes
5. Largest study of high-deductible health plans finds savings, less preventive care
6. Stem Cell Therapy Shrinks Enlarged Hearts
7. Apnea may be cause for awakening and voiding for those with enlarged prostates report Ben-Gurion U.
8. New report says large proportion of colorectal cancer deaths could be prevented
9. PSA screening declines following publication of large trials, guidelines
10. PSA Screening for Prostate Cancer Dips in Large U.S. Health Network
11. Childrens Hospital of Orange County receives largest gift in hospital history
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... TX (PRWEB) , ... February 27, 2017 , ... ... 75,000 customer threshold mark last week. In addition, Discount Power's RCE (Residential Customer ... Energy LLC in March 2014. The company had 800 customers and 2,250 RCEs ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
(Date:2/27/2017)... ... ... New Jersey ranks among the top five states in the entire nation ... advanced services is growing. , Project WE vs C is a focused two-year ... non-profit partners in their fight against cancer and in support of their shared mission ...
(Date:2/26/2017)... Como, Italy (PRWEB) , ... February 26, 2017 ... ... its last call for entries to the 7th Edition of International Social Design ... by Social Design Professionals, Product Designers, System Designers, Governments and Institutions worldwide with ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based in ... Palo Alto, is proud to announce an important upgrade to its geographic information pages, ... care close to home, and by having city-specific pages, NuevaCare is answering that information ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  Today, exocad America and the Biodenta ... new path to produce 510(K) cleared, in-house milled, ... integrated into exocad DentalCAD software. In order to ... Manufacturing Processes (GMP,s) into their organization, sign up ... an audit process. Then, dental labs can use Biodenta,s ...
(Date:2/24/2017)... Research and Markets has announced the addition of ... to 2025" report to their offering. ... The Global Empty Capsules Market is poised to grow ... approximately $2.9 billion by 2025. This industry report analyzes ... as well as regional levels presented in the research scope. The study ...
(Date:2/24/2017)... Feb. 24, 2017  In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Tuesday, March 14, 2017 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
Breaking Medicine Technology: